tDCS in Post-COVID Syndrome: Comparison of Two Targets
COVID-19, Post-COVID-19 Syndrome, Post COVID-19 Condition
About this trial
This is an interventional treatment trial for COVID-19 focused on measuring post-COVID syndrome, brain stimulation, fatigue, cognitive, depression, transcranial direct current stimulation, non-invasive brain stimulation
Eligibility Criteria
Inclusion Criteria: Confirmed diagnosis of COVID-19 at least 6 months before the participation in the study. Diagnosis of post-COVID condition according to WHO criteria. Age 18-65 years. Spanish as native language. Sign of written informed consent. Exclusion Criteria: History of stroke History of traumatic brain injury or central nervous system infection Diagnosis of other neurological or medical disorder that could impact on fatigue. Diagnosis of active psychiatric disorder potentially impacting on fatigue or cognitive function. Chemotherapy or radiotherapy for cancer. Severe sensory deficits (e.g. visual loss) that could limit assessments included int the study protocol. Taking drugs or uncontrolled medical disorder potentially causing or worsening fatigue. Specifically, uncontrolled adrenal insufficiency, miastenic syndromes, thyroid disorders, cardiac failure, chronic kidney disorders and neurodegenerative disorders are excluded. History of abuse of alcohol or other toxics. Any contraindication for transcranial electric stimulation: epilepsy, pregnancy, metallic implants, brain devices, pacemakers, head injuries).
Sites / Locations
- Hospital Clínico San Carlos.Recruiting
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
Left dorsolateral prefrontal cortex
Left M1
15 sessiones of anodal tDCS over the left dorsolateral prefrontal cortex (2 mA, 20 minutes) associated with cognitive training.
15 sessiones of anodal tDCS over the left M1 (2 mA, 20 minutes) associated with cognitive training.